Citi opened an “upside 90-day catalyst watch” on shares of Agilent (A) while keeping a Buy rating on the name with a $185 price target The share overhang of a potential transformational acquisition should be removed with Agilent’s deal for Biocare Medical, the analyst tells investors in a research note. Citi sees the stock’s multiple rebounding.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
